Clinical Trials Logo

Clinical Trial Summary

Implementation of a next-generation sequencing panel of genes to identify deleterious variants in patients with incomplete forms of albinism.


Clinical Trial Description

Scientific context : Albinism is clinically characterised by cutaneous hypopigmentation and ophthalmologic features. These features common to all forms of albinism are foveal hypoplasia, misrouting of the optic nerves at the chiasm, retinal hypopigmentation, translucent irides and nystagmus. The molecular genetic lab at Bordeaux University Hospital is the national reference for the study of this disease. More than 1400 patients have been analyzed with a strategy including next-generation sequencing of the 19 known genes of albinism and array-CGH. Despite this thorough analysis, 25% of patients remain without molecular diagnosis. Our experience tells us that these patients often show an incomplete form of albinism with the presence of only few ophthalmologic signs. The molecular diagnosis is very challenging as the phenotype often overlaps with other ophthalmologic disorders. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04495218
Study type Observational
Source University Hospital, Bordeaux
Contact Vincent MICHAUD, Dr
Phone 0557820353
Email vincent.michaud@chu-bordeaux.fr
Status Recruiting
Phase
Start date November 23, 2020
Completion date June 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06345976 - Functional Impairment in Albinism
Completed NCT00001153 - Visual Function and Ocular Pigmentation in Albinism N/A
Completed NCT03959605 - Genetic Determinant of Foveolar Hypoplasia in Parents of Albinos Children